Scientifically Speaking | Investigating immunity levels from Covid-19 vaccines
3 years, 6 months ago

Scientifically Speaking | Investigating immunity levels from Covid-19 vaccines

Hindustan Times  

Imagine that it is 2022. Creating a test that estimates the amount of immunity requires having what immunologists call correlates of immune protection — biomarkers that serve as measures of the ability to prevent infection or symptomatic Covid-19. Three different approaches point to neutralising antibody levels correlating with immune protection. The goal here is to compare the two sets of people and see if the levels of neutralising antibodies in a person is a good predictor of protection from breakthrough cases. Preliminary results, which were posted on medRxiv on June 24, show that high levels of spike-protein and receptor-binding domain specific neutralising antibodies correlate with a lower chance of symptomatic Covid-19.

Protection Vaccines Infection Immune Vaccine Moderna Levels Immunity High Levels Antibody Neutralising Antibodies Immune Protection  immune  scientifically  immunity  infection  covid19  antibody  protection  investigating  neutralising  antibodies  vaccines  levels  vaccine  speaking

History of this topic

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine
8 months, 1 week ago

‘Safety is primary focus’: Covaxin-developer amid reports on AstraZeneca vaccine

Hindustan Times  

Amid reports over potential rare side effects of the AstraZeneca-Oxford COVID-19 vaccine, Bharat Biotech, which developed the Covaxin, said in a statement that the vaccine was developed with a "single-minded focus on safety first." It stated that Covaxin was the "only Covid vaccine" in government of India's COVID-19 immunisation program to have conducted efficacy trials in India. "@bharatbiotech announcement - …

Covishield more effective than Covaxin: Study
10 months ago

Covishield more effective than Covaxin: Study

New Indian Express  

BENGALURU: Covishield vaccine had higher antibody response compared to Covaxin during the pandemic, according to a study by a consortium of 11 institutions led by scientists from the National Centre for Biological Sciences, Bengaluru. In all, 691 people aged between 18 and 45, mostly from Bengaluru and Pune, were part of the study.’Immunogenicity of SARS - CoV-2 vaccines Covaxin and …

What study on Covishield versus Covaxin vaccine reveals
10 months ago

What study on Covishield versus Covaxin vaccine reveals

The Hindu  

March 07, 2024 10:59 am | Updated March 09, 2024 10:53 am IST - Bengaluru A new study by a consortium of 11 institutes, led by scientists from the National Centre for Biological Sciences, has found that the Covishield vaccine demonstrated more robust immune responses compared to Covaxin. The key findings state that Covishield, leveraging a virus vector to deliver …

’This’ Covid vaccine’s booster dose has best immune response, finds Lancet study
1 year, 11 months ago

’This’ Covid vaccine’s booster dose has best immune response, finds Lancet study

Live Mint  

Covid-19 updates: The booster dose of Covishield vaccine, manufactured by Serum Institute of India Pvt Ltd in India, has the best immune response to the emerging threats of a Covid infection, a study published in The Lancet Regional Health Southeast Asia journal has revealed. In the Covishield primed group with 200 participants, the seropositivity 28 days post booster in the …

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study
2 years ago

Covishield Immune Responses Against Covid Variants Higher Than Covaxin: Study

News 18  

Neutralising antibody responses against the SARS-COV-2 virus and its variants of concern are higher among Covishield recipients than those who took the indigenously made Covaxin, according to a multi-centre study. Covishield elicited immune responses of higher magnitude and breadth than Covaxin in both seronegative individuals and seropositive individuals, across cohorts representing the pre-vaccination immune history of the majority of the …

CORBEVAX offers better immunity as a heterologous booster shot
2 years, 2 months ago

CORBEVAX offers better immunity as a heterologous booster shot

Deccan Chronicle  

HYDERABAD: Heterologous booster shots have gained significance in light of the waning effect of vaccine doses, especially against different variants of the Covid-19 virus. There is an increase in the immune response to the administration of heterologous booster shots on two counts – first cellular immunity and second, neutralizing antibodies. Administering the CORBEVAX vaccine as a heterologous booster dose provides …

Adults may get different vaccine as booster shot instead of Covishield, Covaxin
2 years, 5 months ago

Adults may get different vaccine as booster shot instead of Covishield, Covaxin

Live Mint  

As the government has continued to emphasize Covid booster doses due to the rising number of cases, a panel has recommended a different vaccine for Indian adults. Government panel National Technical Advisory Group on Immunisation has recommended Biological E's Corbevax as a precaution dose for adults fully vaccinated with either Covishield or Covaxin. "Corbevax may be considered for a third/precaution …

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech
2 years, 6 months ago

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years: Bharat Biotech

The Hindu  

Bharat Biotech International Limited, on Friday, announced that COVID-vaccine Covaxin has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The company in its press release said that Bharat Biotech had conducted phase II/III, open-label, and multi-centre study to evaluate the safety, reactogenicity, and immunogenicity Covaxin in healthy children and adolescents in 2-18 years …

Booster with different vaccine gave higher antibody response: CMC study
2 years, 7 months ago

Booster with different vaccine gave higher antibody response: CMC study

The Hindu  

A booster dose with a COVID-19 vaccine different from the one used for the first immunisation raised antibody levels more than a booster with the same vaccine. A Covishield booster following a two-dose Covaxin immunisation gave the highest antibody response, compared with a Covaxin booster following two Covishield shots, but these levels, on their own, were no guarantee against protection …

Fourth Covid-19 vaccine dose provides strong immunity boost: UK study
2 years, 7 months ago

Fourth Covid-19 vaccine dose provides strong immunity boost: UK study

India TV News  

A fourth dose of the Pfizer or Moderna COVID-19 vaccine is safe and boosts antibody levels, even higher than that of a third dose, according to the latest results from a nationwide study in the UK. The findings, published in The Lancet Infectious Disease journal, show that fourth dose mRNA booster vaccines for COVID-19 are well-tolerated in people who received …

AstraZeneca Covid Booster Shot Effective Against Severe Disease, UK Study Finds
2 years, 8 months ago

AstraZeneca Covid Booster Shot Effective Against Severe Disease, UK Study Finds

News 18  

London: The third dose of AstraZeneca COVID-19 vaccine is effective against symptomatic disease and hospitalisation, offering protection comparable to a booster shot of the Pfizer preventive, according to a study conducted in the UK. The results show that after 25 or more weeks since primary vaccination with AstraZeneca, vaccine effectiveness against symptomatic disease post Omicron infection was 8.0 per cent …

'Longer interval between COVID-19 vaccine doses generates nine times higher antibodies'
2 years, 8 months ago

'Longer interval between COVID-19 vaccine doses generates nine times higher antibodies'

Firstpost  

The finding by researchers at the UK Health Security Agency also suggests that eight months after primary infection may be an optimum time to receive the first vaccine in those with prior infection. When analysing dosing intervals, the researchers found that longer dosing interval was associated with antibody levels that were up to nine times higher in naive participants with …

Centre’s decision on mix-and-match boosters likely in two weeks: Official
2 years, 8 months ago

Centre’s decision on mix-and-match boosters likely in two weeks: Official

Hindustan Times  

The government may be able to decide in two weeks whether to mix and match the booster doses of approved Covid-19 vaccines based on India-specific trial data being prepared by the Christian Medical College in Vellore, according to people familiar with the development. CMC Vellore, which was permitted to conduct homologous as well as heterologous booster dose trial by the …

In First Quantitative Sero-survey in Mumbai, 99.93% Participants Found with Covid-19 Antibodies
2 years, 8 months ago

In First Quantitative Sero-survey in Mumbai, 99.93% Participants Found with Covid-19 Antibodies

News 18  

In the first quantitative sero-survey conducted in March this year, COVID-19 antibodies were found in 3,097 out of the 3,099 health and frontline workers, who were examined, the Brihanmumbai Municipal Corporation said. Comparatively, more antibodies were found in the blood samples of the employees, who have taken the preventive or booster doses of COVID-19 vaccines as compared to the fully …

High immune response to COVID variants in breakthrough cases after two Covaxin jabs: ICMR study
2 years, 9 months ago

High immune response to COVID variants in breakthrough cases after two Covaxin jabs: ICMR study

Firstpost  

The study highlights the significance of administering a booster dose or precaution dose of COVID vaccine as it provides better protection against the disease, said Dr Pragya Yadav, a senior scientist at NIV Pune and the lead investigator of the study New Delhi: In a recent ICMR study, breakthrough cases after full vaccination with Covaxin have shown a significant increase …

ICMR Study Has Shown Rise in Antibodies Post Covaxin Booster Dose: MoS Health Tells Rajya Sabha
2 years, 9 months ago

ICMR Study Has Shown Rise in Antibodies Post Covaxin Booster Dose: MoS Health Tells Rajya Sabha

News 18  

An ICMR study to examine the effect of Covaxin's booster dose has shown an increase in the levels of antibodies against SARS-CoV-2, Minister of State for Health Bharati Pravin Pawar told the Rajya Sabha on Tuesday. International data available on booster doses of AstraZeneca and Covishield suggests a three- to four-fold increase in antibody levels after their administration, Pawar said …

Covishield as Booster After 2 Doses of Covaxin Increases Antibodies by 6 Times: Study
2 years, 9 months ago

Covishield as Booster After 2 Doses of Covaxin Increases Antibodies by 6 Times: Study

News 18  

A recent study has found that Covishield is more effective when administered as a booster after two doses of Covaxin as antibodies zoom six-fold, however, the case is not the same when the vaccines are reversed. The study, submitted by Christian Medical College, Vellore, to the Drugs Controller General of India on Wednesday, is the first preliminary scientific evidence from …

COVID: Antibodies improve in quality for months after vaccination, claims study
2 years, 10 months ago

COVID: Antibodies improve in quality for months after vaccination, claims study

India TV News  

For at least six months after Covid-19 vaccination, antibodies produced by immune cells become steadily more formidable and more precisely targeted against the virus that causes Covid-19, according to a study of the antibody response to the Pfizer-BioNTech vaccine. The researchers found that B cells targeted against SARS-CoV-2 persisted in the germinal centres - like boot camps where B cells …

Quality of antibodies improves for months after COVID-19 vaccination: Study
2 years, 10 months ago

Quality of antibodies improves for months after COVID-19 vaccination: Study

Deccan Chronicle  

Washington: Antibodies produced by immune cells become steadily more formidable and precisely targeted against the SARS-CoV-2 virus for at least six months after COVID-19 vaccination, according to a study. "If the virus did not change, most people who got two doses of this vaccine would be in very good shape," said senior study author Ali Ellebedy, an associate professor at …

Omicron News Updates: Schools across Maharashtra to reopen for all classes from 24 Jan, says Varsha Gaikwad
2 years, 11 months ago

Omicron News Updates: Schools across Maharashtra to reopen for all classes from 24 Jan, says Varsha Gaikwad

Firstpost  

12:49 PM Whatsapp Facebook Twitter Omicron News LIVE Updates COVID-19 vaccine booster provides effective antibody protection against Omicron, finds Lancet study A third dose of COVID-19 vaccine increases the level of antibodies that can effectively neutralise the Omicron variant of coronavirus, according to a study published in The Lancet journal. Researchers from Francis Crick Institute and the National Institute for …

COVID-19 vaccine booster provides effective antibody protection against Omicron, says Lancet study
2 years, 11 months ago

COVID-19 vaccine booster provides effective antibody protection against Omicron, says Lancet study

Firstpost  

COVID-19 Vaccine Booster | The study found that in people who had received the Pfizer vaccine for all three doses, antibody levels against Omicron after a third dose were similar to those previously reached against Delta after only two shots. London: A third dose of COVID-19 vaccine increases the level of antibodies that can effectively neutralise the Omicron variant of …

Covid-19: Covaxin booster working against Omicron and Delta, says Bharat Biotech
2 years, 11 months ago

Covid-19: Covaxin booster working against Omicron and Delta, says Bharat Biotech

India Today  

Vaccine manufacturer Bharat Biotech said the booster dose of Covaxin has generated robust neutralising antibody responses against both Omicron and Delta, using a live virus neutralisation assay. Test results show that 100 per cent of the serum samples showed neutralisation of the Delta variant and more than 90% of serum samples showed neutralisation of the Omicron variant, Bharat Biotech said. …

Covaxin booster shot may provide long-term immunity against severe Covid, says Bharat Biotech
3 years ago

Covaxin booster shot may provide long-term immunity against severe Covid, says Bharat Biotech

India Today  

A booster dose of Bharat Biotech's Covid-19 vaccine Covaxin, administered six months after the second dose, could provide long-term immunity from severe SARS-CoV-2 infection, a study by Bharat Biotech and the Indian Council of Medical Research - National Institute of Virology, Pune, has indicated. The study, published on medRxiv and not yet peer-reviewed, said that the Covaxin booster shot is …

COVID: Study suggests AstraZeneca booster works against Omicron
3 years ago

COVID: Study suggests AstraZeneca booster works against Omicron

Al Jazeera  

Findings from the study, which has yet to be peer reviewed, match those from Pfizer-BioNTech and Moderna. AstraZeneca has said that a third dose of its COVID-19 vaccine “significantly” lifted antibody levels against the Omicron coronavirus variant, citing data from a new laboratory study. Boosters ‘limit Omicron spread’ Oxford’s researchers analysed blood samples taken from individuals infected with COVID-19; those …

Booster Doses amid Omicron Scare: Decide Cut-off for Antibody Levels, Prioritise Health Workers
3 years, 1 month ago

Booster Doses amid Omicron Scare: Decide Cut-off for Antibody Levels, Prioritise Health Workers

News 18  

Is my immunity against COVID-19 waning? Researchers at Public Health England posted a preprint in September which builds a strong case for older adults and those with co-morbidities to be prioritised for booster doses if administered Covishield, the viral-vector vaccine from AstraZeneca, which is called ‘Vaxzevria’ in the UK. America’s CDC offers boosters six months after the second dose of …

Mix and matching some COVID vaccines gives high immunity: Study
3 years, 1 month ago

Mix and matching some COVID vaccines gives high immunity: Study

Al Jazeera  

Oxford University study finds mixing a first dose of the Pfizer or Astrazeneca vaccine with a second Moderna shot yields higher antibodies. “I think the data from this study will be especially interesting and valuable to low- and middle-income countries where they’re still rolling out the first two doses of vaccines,” Snape said. “We’re showing … you don’t have to …

Booster dose of six Covid vaccines safe, increases immunity: Lancet study
3 years, 1 month ago

Booster dose of six Covid vaccines safe, increases immunity: Lancet study

Deccan Chronicle  

New Delhi: Six different COVID-19 boosters are safe and elicit strong immune response in people who have previously received a two-dose course of AstraZeneca or Pfizer vaccines, according to a study published in The Lancet journal. Two doses of AstraZeneca and Pfizer vaccines have shown 79 per cent and 90 per cent protection, respectively, against hospitalisation and death after six …

Covaxin shows 50% effectiveness against symptomatic Covid-19, says Lancet study
3 years, 1 month ago

Covaxin shows 50% effectiveness against symptomatic Covid-19, says Lancet study

India Today  

Two doses of Covaxin are 50 per cent effective against the symptomatic disease, according to the first real-world assessment of India's indigenous Covid-19 vaccine published in The Lancet Infectious Diseases journal. Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and …

Vaccine Hesitancy Greatest Threat in Overcoming Covid: Adar Poonawalla
3 years, 1 month ago

Vaccine Hesitancy Greatest Threat in Overcoming Covid: Adar Poonawalla

News 18  

Serum Institute of India CEO Adar Poonawalla on Wednesday termed vaccine hesitancy as the greatest threat in overcoming the COVID-19 pandemic while urging all adults to get vaccinated at the earliest. He said that 200 million doses of the COVID-19 vaccine were lying with the states and people should get themselves vaccinated as soon as possible. Vaccine hesitancy is now …

Covaxin 77.8% Effective Against Covid-19, 65.2% Against Delta Variant: Lancet Study
3 years, 1 month ago

Covaxin 77.8% Effective Against Covid-19, 65.2% Against Delta Variant: Lancet Study

News 18  

Covaxin, a Covid-19 vaccine developed by Hyderabad-based Bharat Biotech, was found to have a 77.8% efficacy rate against symptomatic Covid-19, as per an analysis published in The Lancet. The roll-out of Covaxin can “increase the finite global manufacturing capacity, and improve the insufficient supply of vaccines which disproportionately affects low-income and middle-income countries”, said Chinese researchers Li Jingxin Li and …

Covid vaccinated people with prior infection may have more antibodies: Study
3 years, 2 months ago

Covid vaccinated people with prior infection may have more antibodies: Study

Deccan Chronicle  

Washington: Antibody levels against SARS-CoV-2, the virus that causes COVID-19, stay more durable in people who were infected by the disease and then received two doses of vaccine compared with those who only got immunised, according to a study. After adjusting for vaccine type, age and sex, antibody levels were compared for those with and without prior SARS-CoV-2 infection at …

COVID-19 vaccines more protective than past infection, study shows
3 years, 2 months ago

COVID-19 vaccines more protective than past infection, study shows

LA Times  

A nursing student draws a COVID-19 vaccine into a syringe. A new study shows that vaccinations can offer better protection against COVID-19 than natural immunity from a prior infection. Unvaccinated people who had been infected months earlier were 5 times more likely to get COVID-19 than fully vaccinated people who didn’t have a prior infection, researchers concluded in a new …

China's Inhalable Covid Vaccine Taken As Booster Shot May Boost Antibodies 300-fold
3 years, 2 months ago

China's Inhalable Covid Vaccine Taken As Booster Shot May Boost Antibodies 300-fold

News 18  

An inhalable Covid-19 vaccine developed by China’s CanSino Biologics has shown an increase of 250- to 300-fold in neutralising antibody levels as a booster shot, the media reported. According to latest lab studies by the Chinese drug maker, the aerosolised inhaled adenovirus Type-5 vector-based Covid-19 vaccine, taken after completing two doses of inactivated vaccine shots for half a year, is …

Mix-and-match vaccines highly effective against COVID-19: Lancet study
3 years, 2 months ago

Mix-and-match vaccines highly effective against COVID-19: Lancet study

Deccan Chronicle  

London: People who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine followed by an mRNA vaccine shot had a lower risk of infection compared to those immunised with both doses of the AstraZeneca preventive, according to a nationwide study in Sweden. "However, our study shows a greater risk reduction for people who received an mRNA vaccine after having received …

Covid-specific Antibodies Remain In Breast Milk For 10 Months Post Infection, Finds Study
3 years, 3 months ago

Covid-specific Antibodies Remain In Breast Milk For 10 Months Post Infection, Finds Study

News 18  

Covid infection in breastfeeding women produces virus-neutralising antibodies that remain in their milk for up to 10 months, finds a new study. The study led by Icahn School of Medicine at Mount Sinai Hospital in New York showed that the antibodies in breast milk — Secretory Immunoglobulin A — are different to the Immunoglobulin G antibodies that is found in …

Covid-19 booster shots not appropriate amid high vaccine efficacy: Study
3 years, 3 months ago

Covid-19 booster shots not appropriate amid high vaccine efficacy: Study

India Today  

Vaccine efficacy against severe Covid-19, even for the delta variant, is so high that booster doses for the general population are not appropriate at this stage in the pandemic, according to a review by an international group of scientists published in The Lancet on Monday. Although vaccines are less effective against asymptomatic disease or against transmission than against severe disease, …

New Evidence Points To Antibodies As A Reliable Indicator Of Vaccine Protection
3 years, 4 months ago

New Evidence Points To Antibodies As A Reliable Indicator Of Vaccine Protection

NPR  

New Evidence Points To Antibodies As A Reliable Indicator Of Vaccine Protection Enlarge this image toggle caption Britta Pedersen/dpa/picture alliance via Getty Images Britta Pedersen/dpa/picture alliance via Getty Images When Dr. Anthony Fauci spoke recently at a White House briefing about the need for COVID-19 booster shots, buried in his slideshow of charts and data points was a little-noticed scientific …

FDA set to clear third COVID-19 shot for people with weak immune systems
3 years, 4 months ago

FDA set to clear third COVID-19 shot for people with weak immune systems

LA Times  

U.S. drug regulators are set to clear a third dose of COVID-19 vaccines for people with weak immune systems as a new study showed the benefits of an extra shot in transplant patients. A third dose of Moderna Inc.’s vaccine significantly raised antibody levels against the coronavirus in transplant patients, according a comparison of an extra shot to a placebo …

Mixing of Covishield, Covaxin safe; elicits better immunity: ICMR study
3 years, 5 months ago

Mixing of Covishield, Covaxin safe; elicits better immunity: ICMR study

Live Mint  

Immunization with a combination of first dose of Covishield followed by second dose of Covaxin is not only safe but also elicits better immunogenicity, the Indian Council of Medical Research said on Sunday citing its preprint research. Covishield is the in-country version of the Oxford-AstraZeneca vaccine manufactured by Serum Institute of India, while Covaxin is an inactivated whole virus vaccine …

Covaxin receives Good Manufacturing Practice certificate from Hungary
3 years, 5 months ago

Covaxin receives Good Manufacturing Practice certificate from Hungary

India Today  

Bharat Biotech's Covaxin has received a certificate of Good Manufacturing Practice from the National Institute of Pharmacy and Nutrition Hungary. The certificate of GMP is now listed on the EudraGMDP database, which is the database of the European Community of manufacturing authorisations and certificates of the good manufacturing practice. Read: EU holding back approval for Indian-made AstraZeneca vaccine 'discriminatory', say …

Q&A on vaccine protective effects, booster shot
3 years, 5 months ago

Q&A on vaccine protective effects, booster shot

China Daily  

The National Health Commission has responded to key public concerns about COVID-19 vaccines and disease control policies amid a resurgence of novel coronavirus fueled by the Delta variant in recent weeks. Available data shows that like other vaccines, antibody levels in vaccinated people will go down as time goes by. Six months after full immunization, neutralizing antibodies in people aged …

Q&A on vaccine protective effects, booster shot
3 years, 5 months ago

Q&A on vaccine protective effects, booster shot

China Daily  

The National Health Commission has responded to key public concerns about COVID-19 vaccines and disease control policies amid a resurgence of novel coronavirus fueled by the Delta variant in recent weeks. Available data shows that like other vaccines, antibody levels in vaccinated people will go down as time goes by. Six months after full immunization, neutralizing antibodies in people aged …

Covaxin effective against new Delta Plus variant, says study
3 years, 5 months ago

Covaxin effective against new Delta Plus variant, says study

Hindustan Times  

Covaxin can effectively neutralise the Delta Plus, the vaccine’s manufacturer Bharat Biotech said citing laboratory studies it carried out along with the Indian Council of Medical Research. Bharat Biotech in June said the final efficacy estimates, based on its phase 3 trials, showed Covaxin had an efficacy rate of 77.8% against the Sars-Cov-2 virus that most closely resembles the origin …

‘Covaxin is effective against Delta Plus’
3 years, 5 months ago

‘Covaxin is effective against Delta Plus’

Live Mint  

Bharat Biotech’s coronavirus vaccine Covaxin is effective against the Delta Plus variant of SARS CoV2 virus, showed a study by the Indian Council of Medical Research National Institute of Virology. Scientists evaluated the IgG antibody titer and neutralizing potential of blood sample of covid-19 naive individual’s full doses of Covaxin, covid-19 recovered cases with full dose vaccines, and breakthrough cases …

Pfizer, AstraZeneca Vaccine Antibody Levels May Decline After 2-3 Months: Lancet Study
3 years, 5 months ago

Pfizer, AstraZeneca Vaccine Antibody Levels May Decline After 2-3 Months: Lancet Study

News 18  

Total antibody levels start to wane six weeks after complete immunisation with Pfizer and AstraZeneca vaccines, and can reduce by more than 50 per cent over 10 weeks, according to study published in The Lancet journal. The UCL Virus Watch study also found that antibody levels are substantially higher following two doses of the Pfizer vaccine than after two shots …

Pfizer, AstraZeneca vaccine antibody levels may drop after 2-3 months: Lancet study
3 years, 5 months ago

Pfizer, AstraZeneca vaccine antibody levels may drop after 2-3 months: Lancet study

Deccan Chronicle  

London: Total antibody levels start to wane six weeks after complete immunisation with Pfizer and AstraZeneca vaccines, and can reduce by more than 50 per cent over 10 weeks, according to study published in The Lancet journal. The UCL Virus Watch study also found that antibody levels are substantially higher following two doses of the Pfizer vaccine than after two …

Mixed AstraZeneca-Pfizer shot boosts Covid antibody level: Study
3 years, 5 months ago

Mixed AstraZeneca-Pfizer shot boosts Covid antibody level: Study

India Today  

A mixed vaccination of first AstraZeneca and then a Pfizer Covid-19 shot boosted neutralizing antibody levels by six times compared with two AstraZeneca doses, a study from South Korea showed. The study involved 499 medical workers - 100 receiving mixed doses, 200 taking two doses of the Pfizer/BioNTech shot and the remainder getting two AstraZeneca shots. All showed neutralizing antibodies, …

Covaxin approval soon? WHO chief scientist says Phase-3 trial data looks good
3 years, 6 months ago

Covaxin approval soon? WHO chief scientist says Phase-3 trial data looks good

India Today  

As Hyderabad-based pharma firm Bharat Biotech awaits the World Health Organisation's approval for the emergency use listing for Covaxin, WHO Chief Scientist Soumya Swaminathan has said Covaxin's Phase-3 data looks promising and the vaccine can hopefully be approved by the WHO by mid to late August. In a recent interview, Swaminathan said the Phase-3 trial data of Covaxin looks encouraging …

Final analysis of Covaxin efficacy out; 65.2 per cent effective against Delta
3 years, 6 months ago

Final analysis of Covaxin efficacy out; 65.2 per cent effective against Delta

Deccan Chronicle  

Hyderabad: Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant. The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases while safety analysis shows adverse events reported were similar to placebo, with 12 per cent of subjects experiencing commonly known side …

Discover Related